Alzheimer’s researchers study drug’s efficacy in early stages of disease

Click the blue text above to follow Alzheimer’s disease for free now

years, big

Most drugs used to treat Alzheimer’s disease have been ineffective in clinical trials. Researchers at Indiana University School of Medicine recently used their rigorous process to evaluate the efficacy of a failed clinical trial drug.

< /p>Indiana University School of Medicine July 25 message

from Late-onset Alzheimer’s Model Organism Development and Evaluation for Late-Onset Alzheimer’s Disease (Model – AD) researchers, a researcher at the Indiana University School of Medicine > (Indiana University School of Medicine), Jackson Laboratory, Sage Bionetworks Center, University of Pittsburgh School of Medicine School of Medicine) and a consortium of experts from the University of California, Irvine recently presented at the Alzheimer’s Association’s “Alzheimer’s Disease and Dementia: Translational” Their research was published in the journal Alzheimer’s & Dementia: Translational Research & Clinical Intervention.

Research published on July 14, 2022 in Alzheimer’s & Dementia: Translational Research & Clinical Intervention: 7 On

Adrian Oblak, Ph.D., assistant professor of radiology and imaging sciences at Indiana University School of Medicine and lead author of the paper, said the study was conducted by

strong>Model – A core drug screening pipeline for AD preclinical testing, investigating the efficacy of verubecestat, a beta-secretase (BACE) inhibitor, used in the early stages of Alzheimer’s disease.

,” Oblak said, “In Alzheimer’s disease The efficacy of this drug was also understudied prior to the onset of ALS, making it an ideal compound for Model – AD studies.”

Study In vivo PET/MRI imaging was performed on animal models to measure intracerebral amyloid deposition and glucose uptake, plasma and brain beta-amyloid, and to assess clinical and behavioral characteristics.

Stacey, associate professor of neurobiology and geriatrics at the University of Pittsburgh Institute for Gerontology and senior author of the paper Dr. Rizzo said the study confirms the importance of the consortium (Model – AD) in advancing Alzheimer’s disease research.essential.

Dr. Stacey Rizzo

<--Rizzo said: "

<--Rizzo> AD Consortium brings together experts from Alzheimer’s disease biology, mouse models, genetics, behavioral research, neuropharmacology, and medical imaging to develop research infrastructure that benefits the entire Alzheimer’s disease research community There is currently no cure for Alzheimer’s disease, so it is absolutely necessary to find a cure and develop strategies for prevention.”

Rizzo said, National Institutes of Health The National Institute on Aging (NIA), a division of the National Institutes of Health (NIH), funds the MODEL-AD consortium to build a robust infrastructure to improve preclinical translational research for the larger research community , to accelerate the pace of providing effective and safe treatments for patients at risk of Alzheimer’s disease.

“With our strict and unbiased screening strategy, we were able to prevent obvious β-amyloid deposition, which was expected, however, the same dose range, effectively prevented the formation of amyloid plaques, resulting in similar side effects reported in the clinic and no cognitive improvement,” Oblak said of the study, “so if we were reviewing this compound using this rigorous and unbiased approach, we wouldn’t have prioritized advancing it into clinical trials

Oblak said the results of this study, like all of the animal models, protocols and validation data studied by MODEL-AD, It was quickly made available to all investigators for preclinical drug development under the auspices of NIA. Researchers can visit, this channel to submit compounds for research.

Indiana University School of Medicine founded in 1903


Source: Indiana University School of Medicine

Alzheimer’s researchers study drug efficacy in early stages of disease


Oblak , AL, Cope, ZA, Quinney, SK, et al. Prophylactic evaluation of verubecestat on disease- and symptom-modifying effects in 5XFAD mice. Alzheimer’s Dement. 2022; 8:e12317. .12317


This public The medical information on this website is provided and shared only as an information resource and is not intended for or relied upon for any diagnostic or therapeutic purpose. This information should not be used as a substitute for professional diagnosis or treatment. Please consult your doctor before making any medical decision or guidance regarding a specific medical condition.

Parents care about Alzheimer’s disease